Recombinant factor VIIa reduces bleeding risk in patients on platelet aggregation inhibitors immediately prior to renal transplantation - A retrospective analysis

Urologia Internationalis

Volumn 78, Issue 2, 2007, Pages 135-139

  Loertzer, Hagen ^a   Soukup, Jens ^a   Fornara, Paolo ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Kidney transplantation; Platelet aggregation inhibitors; rFVIIa

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; AGED; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING PARAMETERS; CLINICAL ARTICLE; DIURESIS; FEMALE; GRAFT PERFUSION; HEMATOMA; HEMOSTASIS; HUMAN; INTRAOPERATIVE PERIOD; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOSIS;

AGED; FACTOR VIIA; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE CARE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33846895916     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098071     Document Type: Article

References (25)

1. Hamm C: Neue Thrombozytenaggregationshemmer in der Therapie der instabilen Angina. Z Kardiol 2000;89:1053-1056.
2. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al: Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Lancet 2001;358:527-533.
3. Guesde R, Barrou B, Leblanc I, Ourahma S, Goarin JP, Coriat P, et al: Administration of desmopressin in brain-dead donors and renal function in kidney recipients. Lancet 1998;352:1178-1181.
4. Ruzicka H, Björkman S, Lethagen S, Sterner G: Pharmacokinetics and antidiuretic effect of high-dose desmopressin in patients with chronic renal failure. Pharmacol Toxicol 2003;92:137-142.
5. Murkin JM, Lux J, Shannon NA, Guiraclon GM, Menkis AH, McKenzie FN, et al: Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 1994;107:554-561.
6. Bertrand P, Mazzucotelli JP, Loisance D, Ebsayed A, Delenze P, Chachera JPL: Aprotinine en chirurgie cardiaque chez les patients sous antiaggregants plaquettaires. Arch Malactes Coeur Vaisseaux 1993;86:1471-1474.
7. Kelsey M: The antiplatelet effects of aspirin and related component drugs on the surgical patients. J Post Anaesth Nurs 1993;8:101-103.
8. O'egan DJ, Giannopoulos N, Mediratta N, Kendall SWH, Forni A, Piallai R, et al: Topical aprotinine in cardiac operations. Ann Thorac Surg 1994;58:778-788.
9. Park P, Fewel ME, Garton HJ, Thompson BG, Hoff JT: Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery 2003;53:34-38.
10. Gielen-Wijffels SE, van Mook WN, van der Geest S, Ramsay G: Successful treatment of severe bleeding with recombinant factor VIIa after kidney transplantation. Intensive Care Med 2004;30:1232-1234.
11. Dunkley SM, Mackie F: Recombinant factor VIIa used to control massive haemorrhage during renal transplantation surgery; vascular graft remained patent. Hematology 2003;8:263-264.
12. Sander M, von Heymann C, Kox WJ, Spies CD, Turk I, Loening SA, et al: Recombinant factor VIIa for excessive bleeding after thrombectomy prior to kidney transplantation. Transplantation 2004;77:1912-1913.
13. Goldman S, Copeland J, Moritz M, Henderson W, Zadina K, Ovitt T, et al: Starting aspirin therapy after operation. Circulation 1991;84:520-526.
14. Flurdal PA, Sahlin S: Use of desmopressin to prevent bleeding complications in patient treated with aspirin. Br J Surg 1993;80:723-724.
15. Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A, et al: ABC (Anemia and Blood Transfusion in Critical Care) Investigators: Anemia and blood transfusion in critically ill patients. JAMA 2002;288:1499-1507.
16. Brunson ME, Alexander JW: Mechanisms of transfusion-induced immunosuppression. Transfusion 1990;30:651-658.
17. Keller ME, Jean R, LaMorte WW, Millham F, Hirsch E: Effects of age of transfused blood on length of stay in trauma patients: a preliminary report. J Trauma 2002;53:1023-1025.
18. Wilbourn B, Harrison P, Mackie IJ, Liesner R, Machin SJ: Activation of platelets in whole blood by recombinant factor VIIa by a thrombin-dependent mechanism. Br J Haematol 2003;122:651-661.
19. Stork M, Schilling M, Mickley V, Techt B, Abendroth D: Influence of systemic cyclooxygenase inhibition with single dose aspisol on kinetics of arachidonic acid metabolites in the venous effluate of transplanted kidney grafts in humans. Transplant Proc 1996;28:312-313.
20. Werner W, Klemm A, Wunderlich H, Schubert J: Beeinflusst die Einnahme von Thrombozytenaggregationshemmern die Durchführung einer Nierentransplantation? Urologe A 1998;37:75-78.
21. Hirschl MM, Matzner MP, Huber WO, Binder WO, Roggla G, Derfler K, et al: Effect of desmopressin substitution during organ procurement on early renal allograft function. Nephrol Dial Transplant 1996;11:173-176.
22. Fischer K, Hamza A, Eismann R, Amoury M, Heynemann H, Fornara P: Differential diagnostic use of interleukin patterns in patients being monitored after transplantation. Clin Chim Acta 2001;310:71-80.
23. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al: Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777-785.
24. Stepinska J, Banaszewski M, Konopka A, Szajewski T: Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban. Thromb Haemost 2002;87:355-356.
25. Ng HJ, Koh LP, Lee LH: Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Ann Hematol 2003;82:257-258.